McPherson's (ASX:MCP) share price lifts on takeover developments

The McPherson's Ltd (ASX: MCP) share price is rising today after its board recommended shareholders reject a takeover bid for the company.

| More on:
Turning down AGL shares represented by man placing hands up in front of him and frowning

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The McPherson's Ltd (ASX: MCP) share price is rising today after its board recommended shareholders reject the takeover bid from Gallin Pty Ltd.

At the time of writing, shares in the health and beauty supplier were trading higher at $1.425, up 0.71%. By comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is up 0.84%.

Let's take a closer look at these latest developments and how they might affect the McPherson's share price.

McPherson's brushes off Gallin

In today's ASX statement, McPherson's confirmed its board was unanimously recommending shareholders reject the offer from Gallin to buy 100% of the shares in the company for $1.34 each.

The board said the offer "profoundly undervalued the company".

McPherson's chair Graham Cubbin said Gallin was "exploiting" recent share price weakness to buy the company:

The offer has been opportunistically timed to exploit McPherson's recent share price weakness following a period of challenging trading conditions.

Shareholders who sell their MCP Shares to Gallin will not benefit from any future growth and any share price improvement above recent lows.

In the release, Mr Cubbin told shareholders McPherson's still had significant room for growth.

The company was currently working on a "comprehensive" operational review to identify areas of growth and implement strategies.

At just under $1.43, the current McPherson's share price is trading higher than the Gallin offer of $1.34.

In its pitch to shareholders, Gallin claimed McPherson's was "in urgent need of reinvigoration…" In addition, Gallin said a $46 million capital raising effort by McPherson's in October 2020 followed by a profit downgrade within 1 month of it raised "a number of red flags…" about the company.

McPherson's claimed Gallin was merely trying to "acquire as large an investment exposure as possible to McPherson's at the least possible price". The board did not indicate whether it would be prepared to accept a revised offer from Gallin.

McPherson's share price snapshot

As noted, the McPherson's share price has faced challenges recently. Over the past 12 months, the company's shares have fallen 36.5%. The company has been hit especially hard by the COVID-19 pandemic and international border closures.

McPherson's has a market capitalisation of $183.6 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »

Man with a hand on his head looks at a red stock market chart showing a falling share price.
Share Fallers

Why AIC Mines, ASX, Karoon Energy, and Life360 shares are falling today

These shares are falling more than most on Tuesday. But why?

Read more »

green lithium battery being held by person
Broker Notes

Forget Pilbara Minerals! Expert says this ASX lithium stock could soar 112%

Strategically important.

Read more »